Why is good clinical practice important?
Updated in May 2026
Have you ever thought about the potential consequences when ethical violations or inaccurate research data arise in clinical trials?
Can you imagine a world where the pursuit of medical advancement comes at the expense of ethical conduct and the well-being of participants? Sadly, this is not just a hypothetical scenario; it’s a reality that has plagued the medical research field for far too long.
Few concepts are as important in the field of medical research as Good Clinical Practices (GCP). These internationally recognized guidelines have become the cornerstone for conducting ethical and scientifically sound clinical trials, ensuring that the rights, safety, and well-being of human subjects are paramount.
In this guide, you will find seven powerful reasons why good clinical practice is important, from protecting trial participants and ensuring data reliability to enabling global drug approvals and satisfying the requirements of the FDA, NIH, and EMA. You will also find a clear explanation of why GCP training is needed from a regulatory perspective, the role of the Belmont Report and ethics committees in shaping modern GCP, and how ICH GCP helps pharmaceutical companies bring new therapies to market efficiently.
A clinical trial participant’s life is a careful balancing act between risk and hope. They put their health and welfare in the hands of researchers, believing that the experimental treatments they participate in hold the promise of a better future.
As clinical research professionals, it is our duty to maintain the highest ethical standards and ensure that these trials are conducted with the greatest care and responsibility.
What does ICH GCP stand for, and what is the purpose of GCP in clinical research?
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. GCP provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are respected and protected. ICH GCP training courses equip researchers with the knowledge and skills necessary to adhere to these essential principles. This ensures the safety and well-being of research participants, the integrity of data collected, and the reliability of research findings.
An ICH GCP training course serves as the foundation for conducting ethical clinical research. It gives us the information and abilities needed to protect the rights and well-being of participants, collect accurate and reliable data, and conduct trials in compliance with legal and regulatory requirements. The likelihood of ethical violations, data falsification, and patient harm significantly increases in the absence of proper GCP training.
Good Clinical Practices (GCP) is much more than a set of rules; GCP is a moral code that protects the safety and well-being of research subjects and the accuracy and reliability of the data being collected and produced. When we adhere to the GCP principles, we embark on a path that advances medical knowledge and maintains the trust placed in us by people who bravely volunteer to serve humanity.
The main regulatory agency for clinical trials in the United States, the FDA, has repeatedly emphasized the importance of Good Clinical Practice training. In several warning letters, the FDA cited inadequate GCP training as a contributing factor to several serious noncompliance issues in a clinical trial and as a potential contributor to adverse events and the degradation of public trust in clinical research.
On the other hand, the NHS, the UK’s national health system, expresses similar concerns to the FDA. In a report issued in 2020, the NHS highlighted the importance of ongoing GCP training for clinical researchers to ensure they are up-to-date with the latest guidelines and best practices. The report also stressed the importance of maintaining Good Clinical Practice certification, which demonstrates a commitment to ethical and responsible research.
Medical research requires a careful balance between scientific innovation and ethical responsibility, which is critical. This delicate balance inspired the development of Good Clinical Practices (GCP), a set of internationally accepted principles for the conduct of clinical trials involving human volunteers.
So, why is an ICH GCP training course so important? To answer this, let’s explore the history of clinical research and explore the consequences of non-compliance.
A journey through history: the ethical failures that made good clinical practice necessary
Sadly, the history of clinical research is not without its dark chapters, marked by instances of unethical practices that have caused significant harm to participants. One of the most infamous examples is the Tuskegee Syphilis Study, conducted in Alabama between 1932 and 1972. In this study, African-American men with syphilis were deliberately denied treatment to observe the natural progression of the disease. This unethical experiment highlights the importance of ethical oversight and the need for stringent standards to protect vulnerable participants.
Earlier still, the atrocities committed during World War II medical experiments led directly to the Nuremberg Code of 1947, the first international document to establish voluntary, informed consent as an absolute requirement for any research involving human subjects. This was followed in 1964 by the Declaration of Helsinki, issued by the World Medical Association, which provided physicians and clinical researchers with a broader set of principles for ethical medical research, principles that the GCP guidelines would later codify into enforceable operational standards.
The Belmont Report: the ethical anchor of modern clinical research
A pivotal moment in the history of good clinical practice came in April 1979, when the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research issued the Belmont Report. Named after the Belmont Conference Center in Maryland, where the Commission held its deliberative sessions, this landmark document established three fundamental ethical principles that must govern all research involving human participants:
- Respect for persons: individuals must be treated as autonomous agents, fully informed, and free to make their own decisions about research participation. Those with diminished autonomy are entitled to special protection.
- Beneficence: Researchers must protect participants from harm while maximizing potential benefits and minimizing risks. Research must be justifiable because its benefits outweigh its burdens.
- Justice: the selection of research participants must be equitable. No single group should bear a disproportionate burden of research risks, nor should the benefits of research be available only to some.
These three principles did not remain theoretical. They became the ethical backbone of every major clinical research framework that followed, including the ICH GCP guidelines themselves. Understanding the Belmont Report is therefore essential for understanding why good clinical practice is important: GCP is, in large part, the operational translation of these ethical principles into practical, enforceable standards for clinical trials worldwide. For a comprehensive analysis of the Belmont Report and its connection to modern GCP and the Declaration of Helsinki, read our dedicated guide at PharmaEduCenter.
ICH GCP: a global standard of trust and protection for clinical trial participants
In the 1970s, in response to such atrocities, the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) developed a set of guidelines known as ICH GCP guidelines, which aim to harmonize clinical trial practices across different regions (with representatives from the United States, Europe, and Japan) and ensure that the highest ethical and scientific standards are upheld. These guidelines encompass a comprehensive set of principles that guide every aspect of clinical trial conduct, from study design and planning to data analysis and publication.
To understand the full structure of these principles, including the updated 11 principles introduced under ICH GCP E6(R3), which was finalized in January 2025 and adopted by the FDA in September 2025, see our dedicated guide on the principles of ICH GCP. For a foundational explanation of what ICH is and how it relates to GCP, we also recommend our article What is ICH and GCP?.
What are the 3 main GCP principles?
The rights, safety, and well-being of trial participants are the topmost consideration for ICH GCP guidelines.
They are essential in maintaining the integrity of the clinical research process and in fostering public trust in medical advancements.
Patient safety:
The primary concern of GCP is the safety of the patients participating in clinical trials. Ensuring that patients are not exposed to unnecessary risks is paramount. This involves rigorous oversight of the trial process, careful monitoring of patient health, and immediate reporting and addressing of any adverse events. Maintaining high safety standards protects participants from potential harm and builds public trust in the clinical research process.
Patients’ rights:
Respecting the rights of patients is a cornerstone of GCP. This includes obtaining informed consent, where participants are fully informed about the trial’s purpose, procedures, risks, and benefits before agreeing to take part. It also involves safeguarding their privacy and confidentiality. Participants have the right to withdraw from the trial at any time without any consequences, ensuring their autonomy and respect throughout the clinical study.
Patients’ well-being:
The well-being of patients is a fundamental GCP principle, emphasizing that the benefits of participating in the trial should outweigh any risks. This principle ensures that the physical and mental health of participants are prioritized. Clinical trials are designed and conducted with the welfare of the participants in mind, ensuring that their health, both during and after the trial, is not compromised.
Why is ICH GCP training needed? The regulatory perspective
Good clinical practice is important not only because it is the ethical thing to do, but also because it is required or expected by the regulatory landscape governing clinical research in the United States and globally. Understanding why ICH GCP training is needed from a regulatory standpoint is essential for anyone working in clinical trials, whether as an investigator, study coordinator, clinical research associate, or sponsor representative.
Is ICH GCP training required by the FDA?
This is one of the most common questions asked by clinical research professionals, and the answer requires some nuance. FDA regulations do not specify a named minimum GCP training requirement. However, the FDA does require full compliance with Good Clinical Practice standards for all studies conducted under an Investigational New Drug (IND) application or Investigational Device Exemption (IDE), as outlined in 21 CFR Part 312 and 21 CFR Part 812. The FDA formally adopted ICH GCP E6(R2) as official guidance in March 2018, and the final version of ICH GCP E6(R3) was published by the FDA in September 2025.
In practice, this means GCP compliance is effectively mandatory for FDA-regulated research, and GCP training is the standard mechanism for demonstrating that investigators and site personnel are qualified to conduct such trials. Under 21 CFR 312.53(a), industry sponsors are responsible for selecting investigators qualified by training and experience, which in practice means verifying that ICH GCP training has been completed before a site is activated.
NIH policy: ICH GCP training is mandatory for federally funded trials
Beyond FDA-regulated studies, the National Institutes of Health (NIH) issued a formal policy in 2017 explicitly requiring that all NIH-funded investigators and staff involved in the conduct, oversight, or management of clinical trials complete ICH GCP training consistent with ICH E6 principles. This policy applies regardless of whether the study is also FDA-regulated, meaning that good clinical practice training online is now a standard requirement across virtually all federally funded clinical research in the United States.
Major research institutions, including Johns Hopkins Medicine, the University of Pittsburgh, and the University of Wisconsin, have extended this requirement to all clinical trials conducted at their sites, whether or not federally funded. This institutional adoption reflects how central ICH GCP training has become to the culture of responsible clinical research.
EMA, MHRA, and international GCP regulatory requirements
Outside the United States, GCP compliance is a legal obligation in the European Union under the EU Clinical Trials Regulation (No. 536/2014), enforced by the European Medicines Agency (EMA). In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) similarly requires GCP compliance for all trials involving investigational medicinal products. In both regions, demonstrated GCP training is an expectation for all investigators and site staff before a trial can be authorized to begin. The GCP regulatory requirement, in other words, is global in scope, and failing to meet it can mean the difference between a successful submission and a rejected dataset.
For ICH GCP good clinical practice training online that aligns with both FDA and ICH E6(R3) requirements, explore our ICH GCP courses at PharmaEduCenter, which meet the TransCelerate mutual recognition criteria and are accepted by pharmaceutical sponsors worldwide.
How does ICH GCP help pharmaceutical companies?
While the primary purpose of good clinical practice is to protect participants and ensure data integrity, ICH GCP also delivers significant practical benefits to pharmaceutical companies and biopharmaceutical sponsors. Understanding how ICH GCP helps pharmaceutical companies is a key part of understanding why good clinical practice is important to the drug development ecosystem as a whole.
Global data acceptance and faster drug approvals
One of the most important contributions of ICH GCP to the pharmaceutical industry is the global acceptance of clinical trial data. Because ICH GCP is recognized by regulatory authorities in the United States, Europe, Japan, and many other countries, data generated in a trial conducted according to ICH GCP standards can be submitted to multiple regulatory agencies without needing to repeat the trial to meet different national requirements. This harmonization, which is the central mission of the International Council for Harmonisation (ICH), dramatically reduces the time and cost involved in bringing a new medicine to patients.
Reduced costs and eliminated redundancies
Before harmonized ICH GCP guidelines existed, pharmaceutical companies conducting multinational trials often had to run separate or substantially adapted trials for each major market, simply to meet different national regulatory standards. ICH GCP eliminated this redundancy. By following a single globally recognized standard, sponsors avoid duplicating studies, reduce administrative overhead, and significantly lower development costs, all of which ultimately help new therapies reach patients faster. According to a review published in the Biomedical Imaging and Interventional Journal, ICH GCP was specifically designed to minimize human exposure to investigational products, improve data quality, speed up marketing of new drugs, and decrease costs to both sponsors and the public.
Data integrity and protection against regulatory action
ICH GCP provides pharmaceutical companies with a clear, auditable framework for managing clinical data management throughout a trial. Adherence to GCP ensures that data is attributable, legible, contemporaneous, original, and accurate, principles commonly summarized under the ALCOA standard, expanded in E6(R3) to ALCOA++. A trial that follows GCP produces results that regulators can trust and that courts can rely on. Conversely, a trial with GCP violations can result in the rejection of an entire dataset, invalidating years of research and costing millions of dollars in sunk investment.
Reputation, trust, and investor confidence
For pharmaceutical companies, consistent GCP compliance builds credibility with regulators, healthcare professionals, investors, and the public. Companies with a strong GCP compliance record are better positioned to attract clinical trial sites, enter international partnerships, and maintain the public trust that is essential for volunteer recruitment. This is why ensuring that all personnel hold current ICH GCP certification is not just a regulatory checkbox; it is a business imperative and a marker of organizational maturity.
The role of the ethics committee in why good clinical practice matters
No discussion of why good clinical practice is important is complete without addressing the role of the ethics committee, known as the Institutional Review Board (IRB) in the United States, or the Independent Ethics Committee (IEC) in international settings. Under ICH GCP guidelines, every clinical trial must be reviewed and approved by an IRB/IEC before it begins, and it must remain under ongoing ethics committee oversight for the duration of its conduct.
What does an ethics committee do in a clinical trial?
The ethics committee serves as an independent safeguard for trial participants. Its core responsibilities under ICH GCP include the following:
- Reviewing the trial protocol to confirm that the study design is ethically sound, that risks are proportionate to potential benefits, and that the trial is scientifically justified.
- Approving the informed consent process and the content of the consent form, ensuring that participants receive complete, understandable information before agreeing to enroll.
- Monitoring ongoing safety by receiving and reviewing adverse event reports and any protocol amendments submitted during the trial.
- Protecting vulnerable populations, such as children, pregnant women, and individuals with diminished capacity, who may be enrolled as trial participants.
- Reviewing investigator qualifications to confirm that the trial team, including the principal investigator, has the necessary training, including current ICH GCP Good Clinical Practice certification, to conduct the study safely.
Why the ethics committee is central to ICH GCP
The ethics committee is the institutional embodiment of the Belmont Report’s principles of respect for persons, beneficence, and justice. It ensures that no clinical trial can begin or continue without independent human oversight that is separate from the interests of the sponsor, the investigator, or the institution. This independence is the cornerstone of the ethical framework that makes good clinical practice meaningful rather than merely procedural. For a full overview of how IRBs and IECs function within the broader clinical trial quality framework, see our related guide on why ICH E8 is essential for safe and reliable clinical trials.
The risks of GCP non-compliance: harm to participants and research integrity
Failure to adhere to GCP guidelines can have far-reaching consequences, both for the participants involved and for the integrity of medical research. Some of the potential risks of non-compliance include:
- Harm to participants: Participants may be exposed to unnecessary risks or even harm due to inadequate safety measures or oversight.
- Loss of public trust: Non-compliance can erode public trust in clinical research and hinder the development of new therapies.
- Regulatory action: Non-compliance may lead to regulatory investigations, fines, and even criminal charges.
- Legal challenges: Participants or their families may file lawsuits if they believe they have been harmed because of non-compliance.
- Rejection of clinical data: regulatory agencies, including the FDA and EMA, may reject an entire trial dataset if material GCP violations are found, invalidating years of research investment and potentially delaying the approval of a treatment that patients need.
- Damage to the sponsor’s reputation: GCP violations become part of the public record through warning letters and inspection reports. They can affect investor confidence, the ability to recruit future trial sites and participants, and long-term brand credibility in the pharmaceutical and biotech sectors.
Why ongoing good clinical practice training and certification matter
GCP guidelines are regularly updated to reflect new scientific knowledge, regulatory requirements, and best practices. Good Clinical Practice training is essential for researchers and clinical trial staff to stay up-to-date with the latest GCP guidelines and ensure that their work meets the highest ethical and scientific standards.
The publication of ICH GCP E6(R3) in January 2025 and its adoption by the FDA in September 2025 represent the most significant revision to GCP guidelines in nearly a decade. E6(R3) introduces a risk-based, proportionate approach to clinical trials, with a stronger emphasis on quality by design, the use of digital technologies, decentralized trial elements, and fit-for-purpose documentation practices. For clinical research professionals, refreshing your good clinical practice certification training to reflect these changes is now both a professional obligation and a regulatory expectation.
Our commitment to professional development: enroll in our ICH GCP training course
At PharmaEduCenter, we recognize the critical role of GCP in safeguarding the future of medical research. PharmaEduCenter is committed to providing high-quality GCP training that empowers researchers and clinical trial staff to conduct ethical and reliable research. Our comprehensive Good Clinical Practice training course provides essential knowledge and skills to researchers and clinical trial staff, enabling them to conduct ethical and reliable research that protects participants and contributes to the advancement of medical science. We also offer regular updates on the latest GCP guidelines to ensure that our learners stay informed and compliant.
Our Good Clinical Practice training is convenient and attractive because of flexibility of access. Also, our applied learning integrates adult learning methods, such as interactive feedback and case studies, providing a higher degree of knowledge retention.
How long does it take to complete good clinical practice certification?
The duration of a GCP training course varies depending on how many modules are included. Modules contain detailed content, images, supporting materials (such as case studies), and a quiz. Learners can complete the modules at their own pace.
Our ICH GCP training course for investigators and site personnel, which is primarily focused on ICH GCP Section 4, can take approximately 2.5 hours to complete.
Our ICH GCP training course, which covers all ICH GCP modules and is tailored to professionals working in the pharmaceutical industry or investigators, can take up to 6 hours to complete.
How do you get Good Clinical Practice Certification?
To obtain ICH GCP certification, you must first complete a specific GCP training course that demonstrates your knowledge and understanding of Good Clinical Practice principles.
Attendees will receive a GCP training certificate upon completion, demonstrating their awareness and understanding of ICH-GCP requirements. This certificate is proof of due diligence, as mandated by government regulatory agencies.
At PharmaEduCenter, after completing your course, you can download your Good Clinical Practice Certification; therefore, you should be able to provide evidence of completion.
How long is a GCP certificate valid for?
If you work for an organization or institution, you will need to check your standard operating procedures (SOPs). This will define how often you need to renew your GCP training by doing a GCP Refresher course. Organizations and institutions will probably recommend a GCP refresher training every 2 to 3 years to keep up with best practices.
Besides, auditors and inspectors performing site’s audits or inspections will look for GCP certifications or GCP refresher training from the principal investigator and site staff at least every 3 years.
Under the NIH GCP training policy, research personnel on NIH-funded clinical trials are required to renew their training every 3 years. Given the recent publication of ICH GCP E6(R3), now is an especially important time to renew your Good Clinical Practice certification training, as the updated guideline introduces substantive changes to how trials must be designed, conducted, documented, and overseen. Staying current with E6(R3) ensures your site is prepared for inspections and audit-ready at all times.
Who is required to complete a GCP training course?
All investigators and research staff who are involved in the conduct, oversight, or management of clinical trials of drugs, biologics, and devices must complete training in Good Clinical Practice (GCP) and refresh it periodically, consistent with the principles of the International Conference on Harmonisation (ICH) E6 (R3).
This includes, but is not limited to, principal investigators, co-investigators, study coordinators, clinical research associates (CRAs), clinical data managers, pharmacists involved in investigational product handling, and anyone responsible for obtaining informed consent from trial participants. Understanding clinical data management principles and good documentation practices is an essential part of GCP compliance for data-facing roles. For guidance on setting up your clinical trial site, assigning staff roles, and meeting investigator responsibilities, visit our online pharma courses page, which includes our course on the fundamentals of clinical trials.
What is TransCelerate BioPharma?
TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design, and facilitate the implementation of solutions designed to drive the efficient, effective, and high-quality delivery of new medicines.
One of the first solutions delivered by Site Qualification and Training Solutions (SQT) was a set of minimum criteria to enable a voluntary mutual recognition process of GCP training across member companies. This allows clinical trial investigators and other site personnel to complete GCP training, which may be recognized by other TransCelerate member companies, making it unnecessary to train separately for each participating company.
At PharmaEduCenter, our Good Clinical Practice training meets the criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma, as necessary to enable mutual recognition of GCP training among trial sponsors. This will ensure your course is mutually accepted across organizations so that you may qualify for the time period without needing retraining for each new trial or sponsor.
Key takeaways: why is good clinical practice important?
- GCP protects trial participants. The primary reason good clinical practice is important is the protection of the rights, safety, and well-being of every person who volunteers to participate in a clinical trial.
- GCP ensures reliable, trustworthy data. Without GCP, clinical trial data cannot be trusted by regulators, physicians, or patients. The entire drug approval system depends on the integrity of trial data.
- The Belmont Report is the ethical foundation. The three principles established by the Belmont Report in 1979, respect for persons, beneficence, and justice, are the moral basis from which GCP principles were built.
- Ethics committees are independent guardians. IRBs and IECs provide the independent oversight that prevents researchers and sponsors from prioritizing their interests above those of participants.
- GCP training is effectively required. The FDA requires GCP compliance for all IND and IDE studies; industry sponsors must verify investigator qualifications through GCP training. The NIH mandates GCP training for all investigators on federally funded clinical trials. The EMA and MHRA require it by law for EU and UK trials, respectively.
- ICH GCP helps pharmaceutical companies. By harmonizing clinical trial standards globally, ICH GCP enables international data acceptance, reduces development costs and timelines, ensures data integrity, and builds the regulatory and public trust that pharmaceutical companies depend on.
- GCP evolves, stay current. ICH GCP E6(R3), finalized in January 2025 and adopted by the FDA in September 2025, reflects the latest scientific and technological advances. Refreshing your good clinical practice certification training is now essential for compliance.
Conclusion: join the community of responsible researchers
Given the current trend of increasingly complex and frequently international clinical studies, it is more important than ever to comprehend GCP principles and apply them rigorously at every stage of the trial lifecycle.
Good clinical practice is not just a regulatory requirement. It is the promise that every person who volunteers for a clinical trial will be treated with dignity, that their data will be used honestly, and that the results will genuinely serve the advancement of human health. From the Nuremberg Code to the Belmont Report, from the Declaration of Helsinki to ICH GCP E6(R3), every step in the history of clinical research ethics has been a step toward keeping that promise.
Enroll in our ICH GCP training course and obtain your ICH GCP certification today! Become part of the global community of responsible researchers committed to upholding the highest ethical standards in clinical research. Together, we can ensure that medical breakthroughs are developed in a safe and ethical manner, benefiting humanity for generations to come.
Whether you are just entering clinical research or refreshing your knowledge to reflect the new ICH GCP E6(R3) standard, our good clinical practice training online provides everything you need to meet regulatory expectations, protect the participants who trust you with their health, and advance your career in clinical research with confidence.
🎓 Are you ready to get your ICH GCP certification?
FAQ: good clinical practice
Why is good clinical practice important in clinical research?
Good clinical practice is important in clinical research because it protects the rights, safety, and well-being of every trial participant while ensuring that the data generated is reliable, accurate, and acceptable to regulatory authorities worldwide. Without GCP, there would be no consistent ethical or scientific standard governing how clinical trials are designed, conducted, or reported, and no reliable basis on which to approve new medicines.
Is GCP training required by the FDA?
The FDA does not specify a named GCP training program by regulation, but it does require full GCP compliance for all studies conducted under an IND or IDE. Industry sponsors must under 21 CFR 312.53(a) select investigators qualified by training and experience, which in practice means verifying GCP training. The NIH explicitly mandates GCP training for all investigators and staff on NIH-funded clinical trials. GCP training is therefore effectively required for virtually all clinical research conducted in the United States.
What is the Belmont Report and how does it relate to GCP?
The Belmont Report is a 1979 US government document that established the three core ethical principles for all research involving human subjects: respect for persons, beneficence, and justice. These principles are the direct ethical foundation of GCP. Every major element of good clinical practice, from informed consent to independent ethics committee review, can be traced back to one or more of the Belmont Report’s three principles. For a detailed guide, read our article on the Belmont Report and GCP.
How does ICH GCP help pharmaceutical companies?
ICH GCP helps pharmaceutical companies by creating a globally accepted standard for clinical trial data, eliminating the need to repeat trials for different national regulatory agencies. This harmonization reduces costs, speeds drug approvals, ensures data integrity, and builds the regulatory and public trust that pharmaceutical companies depend on to bring new therapies to market. It also reduces legal and regulatory risk by providing a clear, auditable framework for trial conduct.
What is the role of an ethics committee in GCP?
Under ICH GCP guidelines, every clinical trial must be reviewed and approved by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB) before it begins. The ethics committee reviews the trial protocol, approves the informed consent process, monitors ongoing safety, protects vulnerable participants, and confirms investigator qualifications, including GCP training. It is the independent institutional safeguard that gives good clinical practice its ethical credibility and enforceability.
How often do I need to renew my GCP certification?
Most regulatory agencies, institutional policies, and standard operating procedures recommend renewing GCP certification every 2 to 3 years. The NIH requires renewal every 3 years for personnel on NIH-funded trials. Given the significant updates introduced by ICH GCP E6(R3), refreshing your good clinical practice certification training is especially important even if your current renewal date has not yet arrived.
Who needs to complete GCP training?
All investigators, co-investigators, study coordinators, clinical research associates (CRAs), clinical data managers, pharmacists involved in investigational product handling, and any other staff involved in the design, conduct, oversight, or management of clinical trials are expected to complete GCP training. This includes personnel working on FDA-regulated studies, NIH-funded trials, EU/UK trials, and any trial where the sponsor requires demonstrated GCP competence as a condition of site participation.
